Search

Your search keyword '"ten Brinke, Anja"' showing total 381 results
Start Over Author "ten Brinke, Anja"
381 results on '"ten Brinke, Anja"'

2. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses

Author

van Allaart, Renée CF., Baars, Adája E., Bekkenk, Marcel W., Bemelman, Frederike J., Boekel, Laura, Bos, Amélie V., Bosma, Angela L., Broens, Bo, Brusse, Esther, Busch, Matthias H., Cristianawati, Olvi, van Doorn, Pieter A., Elias, George, van Els, Cécile ACM., van Gils, Marit J., Goedee, H Stephan, Hijnen, Dirk Jan, Hilhorst, Marc L., Horváth, Barbara, Jallah, Papay BP., de Jongh, Rivka, Mirfazeli, Elham S., Musters, Annelie H., Keijser, Jim BD., van Kempen, Zoé LE., Killestein, Joep, Kreher, Christine, de Leeuw, Karina, van der Kooi, Anneke J., van Ouwerkerk, Lotte, van Paassen, Pieter, Cabeza, Virginia Palomares, Parra Sanchez, Agner R., Ludo van der Pol, W., Post, Nicoline F., Raaphorst, Joop, Ruiter, Annabel M., Rutgers, Abraham, Schreurs, Corine RG., Spuls, Phyllis I., Takkenberg, R Bart, Tas, Sander W., Teng, YK Onno, Vegting, Yosta, Verschuuren, Jan JGM., Voskuyl, Alexandre E., de Wit, Jelle, Wolbink, Gerrit J., van der Woude, Diane, Zwinderman, Koos AH., van den Dijssel, Jet, Duurland, Mariël C., Konijn, Veronique AL., Kummer, Laura YL., Hagen, Ruth R., Kuijper, Lisan H., Wieske, Luuk, van Dam, Koos PJ., Stalman, Eileen W., Steenhuis, Maurice, Geerdes, Dionne M., Mok, Juk Yee, Kragten, Angela HM., Menage, Charlotte, Koets, Lianne, Veldhuisen, Barbera, Verstegen, Niels JM., van der Schoot, C Ellen, van Esch, Wim JE., D'Haens, Geert RAM., Löwenberg, Mark, Volkers, Adriaan G., Rispens, Theo, Kuijpers, Taco W., Eftimov, Filip, van Gisbergen, Klaas PJM., van Ham, S Marieke, ten Brinke, Anja, and van de Sandt, Carolien E.

Published
2024
Full Text
View/download PDF

3. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

Author

van Dam, Koos P. J., Volkers, Adriaan G., Wieske, Luuk, Stalman, Eileen W., Kummer, Laura Y. L., van Kempen, Zoé L. E., Killestein, Joep, Tas, Sander W., Boekel, Laura, Wolbink, Gerrit J., van der Kooi, Anneke J., Raaphorst, Joost, Takkenberg, R. Bart, D’Haens, Geert R. A. M., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Hilhorst, Marc L., Vegting, Yosta, Bemelman, Frederike J., Voskuyl, Alexandre E., Broens, Bo, Sanchez, Agner Parra, van Els, Cécile A. C. M., de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J. G. M., Ruiter, Annabel M., van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Renée C. F., Teng, Y. K. Onno, van Paassen, Pieter, Busch, Matthias H., Jallah, Papay B. P., Brusse, Esther, van Doorn, Pieter A., Baars, Adája E., Hijnen, Dirk Jan, Schreurs, Corine R. G., van der Pol, W. Ludo, Goedee, H. Stephan, Steenhuis, Maurice, Keijzer, Sofie, Keijser, Jim B. D., Cristianawati, Olvi, ten Brinke, Anja, Verstegen, Niels J. M., van Ham, S. Marieke, Rispens, Theo, Kuijpers, Taco W., Löwenberg, Mark, and Eftimov, Filip

Published
2023
Full Text
View/download PDF

5. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

Author

de Jongh, Rivka, van de Sandt, Carolien, Kuijper, Lisan, Duurland, Mariel, Hagen, Ruth, van den Dijssel, Jet, Kreher, Christine, Bos, Amelie, Palomares Cabeza, Viriginia, Konijn, Veronique, Elias, George, Vallejo, Juan, van Gils, Marrit, Ashhurst, Tom, Nejentsev, Sergey, Mirfazeli, Elham, Boekel, Laura, Stalman, Eileen W, Wieske, Luuk, Hooijberg, Femke, van Dam, Koos P J, Besten, Yaëlle R, Kummer, Laura Y L, Steenhuis, Maurice, van Kempen, Zoé L E, Killestein, Joep, Volkers, Adriaan G, Tas, Sander W, van der Kooi, Anneke J, Raaphorst, Joost, Löwenberg, Mark, Takkenberg, R Bart, D'Haens, Geert R A M, Spuls, Phyllis I, Bekkenk, Marcel W, Musters, Annelie H, Post, Nicoline F, Bosma, Angela L, Hilhorst, Marc L, Vegting, Yosta, Bemelman, Frederike J, Voskuyl, Alexandre E, Broens, Bo, Parra Sanchez, Agner, van Els, Cécile A C M, de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J G M, Ruiter, Annabel M, van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Cornelia F, Teng, Y K Onno, van Paassen, Pieter, Busch, Matthias H, Jallah, Papay B P, Brusse, Esther, van Doorn, Pieter A, Baars, Adája E, Hijnen, Dirk Jan, Schreurs, Corine R G, van der Pol, W Ludo, Goedee, H Stephan, Vogelzang, Erik H, Leeuw, Maureen, Atiqi, Sadaf, van Vollenhoven, Ronald, Gerritsen, Martijn, van der Horst-Bruinsma, Irene E, Lems, Willem F, Nurmohamed, Mike T, Boers, Maarten, Keijzer, Sofie, Keijser, Jim, Boogaard, Arend, Cristianawati, Olvi, ten Brinke, Anja, Verstegen, Niels J M, Zwinderman, Koos A H, van Ham, S Marieke, Rispens, Theo, Kuijpers, Taco W, Wolbink, Gertjan, and Eftimov, Filip

Published
2022
Full Text
View/download PDF

6. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

Author

de Jongh, R., van de Sandt, C.E., Kuijper, L., Duurland, M., Hagen, R.R., van den Dijssel, J., Kreher, C., Bos, A., Palomares Cabeza, V., Konijn, V.A.L., Elias, G., Vallejo, J.G., van Gils, M.J., Ashhurst, T.M., Nejentsev, S., Mirfazeli, E.S., Wieske, Luuk, van Dam, Koos P J, Steenhuis, Maurice, Stalman, Eileen W, Kummer, Laura Y L, van Kempen, Zoé L E, Killestein, Joep, Volkers, Adriaan G, Tas, Sander W, Boekel, Laura, Wolbink, Gerrit J, van der Kooi, Anneke J, Raaphorst, Joost, Löwenberg, Mark, Takkenberg, R Bart, D'Haens, Geert R A M, Spuls, Phyllis I, Bekkenk, Marcel W, Musters, Annelie H, Post, Nicoline F, Bosma, Angela L, Hilhorst, Marc L, Vegting, Yosta, Bemelman, Frederike J, Voskuyl, Alexandre E, Broens, Bo, Sanchez, Agner Parra, van Els, Cécile A C M, de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J G M, Ruiter, Annabel M, van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Renée C F, Teng, Y K Onno, van Paassen, Pieter, Busch, Matthias H, Jallah, Papay B P, Brusse, Esther, van Doorn, Pieter A, Baars, Adája E, Hijnen, Dirk Jan, Schreurs, Corine R G, van der Pol, W Ludo, Goedee, H Stephan, Keijzer, Sofie, Keijser, Jim B D, Boogaard, Arend, Cristianawati, Olvi, ten Brinke, Anja, Verstegen, Niels J M, Zwinderman, Koos A H, van Ham, S Marieke, Kuijpers, Taco W, Rispens, Theo, and Eftimov, Filip

Published
2022
Full Text
View/download PDF

7. Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases

Author

Wieske, Luuk, Kummer, Laura Y. L., van Dam, Koos P. J., Stalman, Eileen W., van der Kooi, Anneke J., Raaphorst, Joost, Löwenberg, Mark, Takkenberg, R. Bart, Volkers, Adriaan G., D’Haens, Geert R. A. M., Tas, Sander W., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Hilhorst, Marc L., Vegting, Yosta, Bemelman, Frederike J., Killestein, Joep, van Kempen, Zoé L. E., Voskuyl, Alexandre E., Broens, Bo, Sanchez, Agner Parra, Wolbink, Gertjan, Boekel, Laura, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J. G. M., Ruiter, Annabel M., van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Cornelia F., Teng, Y. K. Onno, van Paassen, Pieter, Busch, Matthias H., Jallah, B. Papay, Brusse, Esther, van Doorn, Pieter A., Baars, Adája E., Hijnen, Dirkjan, Schreurs, Corine R. G., van der Pol, W. Ludo, Goedee, H. Stephan, Steenhuis, Maurice, Rispens, Theo, ten Brinke, Anja, Verstegen, Niels J. M., Zwinderman, Koos A. H., van Ham, S. Marieke, Kuijpers, Taco W., and Eftimov, Filip

Published
2022
Full Text
View/download PDF

8. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination

Author

Verstegen, Niels J M, primary, Hagen, Ruth R, additional, Kreher, Christine, additional, Kuijper, Lisan H, additional, Dijssel, Jet van den, additional, Ashhurst, Thomas, additional, Kummer, Laura Y L, additional, Palomares Cabeza, Virginia, additional, Steenhuis, Maurice, additional, Duurland, Mariël C, additional, Jongh, Rivka de, additional, Schoot, C Ellen van der, additional, Konijn, Veronique A L, additional, Mul, Erik, additional, Kedzierska, Katherine, additional, van Dam, Koos P J, additional, Stalman, Eileen W, additional, Boekel, Laura, additional, Wolbink, Gertjan, additional, Tas, Sander W, additional, Killestein, Joep, additional, Rispens, Theo, additional, Wieske, Luuk, additional, Kuijpers, Taco W, additional, Eftimov, Filip, additional, van Kempen, Zoé L E, additional, van Ham, S Marieke, additional, ten Brinke, Anja, additional, and van de Sandt, Carolien E, additional

Published
2024
Full Text
View/download PDF

9. Longitudinal rheumatoid factor autoantibody responses after SARS-CoV-2 vaccination or infection

Author

Keijzer, Sofie, primary, Oskam, Nienke, additional, Ooijevaar-de Heer, Pleuni, additional, Steenhuis, Maurice, additional, Keijser, Jim B.D., additional, Wieske, Luuk, additional, van Dam, Koos P.J., additional, Stalman, Eileen W., additional, Kummer, Laura Y.L., additional, Boekel, Laura, additional, Kuijpers, Taco W., additional, ten Brinke, Anja, additional, van Ham, S. Marieke, additional, Eftimov, Filip, additional, Tas, Sander W., additional, Wolbink, Gerrit J., additional, and Rispens, Theo, additional

Published
2024
Full Text
View/download PDF

10. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization.

Author

Fuchs, Anke, Gliwiński, Mateusz, Grageda, Nathali, Spiering, Rachel, Abbas, Abul K, Appel, Silke, Bacchetta, Rosa, Battaglia, Manuela, Berglund, David, Blazar, Bruce, Bluestone, Jeffrey A, Bornhäuser, Martin, Ten Brinke, Anja, Brusko, Todd M, Cools, Nathalie, Cuturi, Maria Cristina, Geissler, Edward, Giannoukakis, Nick, Gołab, Karolina, Hafler, David A, van Ham, S Marieke, Hester, Joanna, Hippen, Keli, Di Ianni, Mauro, Ilic, Natasa, Isaacs, John, Issa, Fadi, Iwaszkiewicz-Grześ, Dorota, Jaeckel, Elmar, Joosten, Irma, Klatzmann, David, Koenen, Hans, van Kooten, Cees, Korsgren, Olle, Kretschmer, Karsten, Levings, Megan, Marek-Trzonkowska, Natalia Maria, Martinez-Llordella, Marc, Miljkovic, Djordje, Mills, Kingston HG, Miranda, Joana P, Piccirillo, Ciriaco A, Putnam, Amy L, Ritter, Thomas, Roncarolo, Maria Grazia, Sakaguchi, Shimon, Sánchez-Ramón, Silvia, Sawitzki, Birgit, Sofronic-Milosavljevic, Ljiljana, Sykes, Megan, Tang, Qizhi, Vives-Pi, Marta, Waldmann, Herman, Witkowski, Piotr, Wood, Kathryn J, Gregori, Silvia, Hilkens, Catharien MU, Lombardi, Giovanna, Lord, Phillip, Martinez-Caceres, Eva M, and Trzonkowski, Piotr

Subjects
T regulatory cells, cell therapy, good manufacturing practice, immune tolerance, immunotherapy, minimum information model, Autoimmune Disease, Vaccine Related, Inflammatory and Immune System, Immunology, Medical Microbiology
Abstract

Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. While the number of clinical trials testing Tregs is already substantial, it seems to be crucial to provide some standardized characteristics of Treg products in order to minimize the problem. We have previously developed reporting guidelines called minimum information about tolerogenic antigen-presenting cells, which allows the comparison between different preparations of tolerance-inducing antigen-presenting cells. Having this experience, here we describe another minimum information about Tregs (MITREG). It is important to note that MITREG does not dictate how investigators should generate or characterize Tregs, but it does require investigators to report their Treg data in a consistent and transparent manner. We hope this will, therefore, be a useful tool facilitating standardized reporting on the manufacturing of Tregs, either for research purposes or for clinical application. This way MITREG might also be an important step toward more standardized and reproducible testing of the Tregs preparations in clinical applications.

Published
2017

11. Formation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment.

Author

Berkhout, Lea Catharina, I'Ami, Merel Jeanne, Kruithof, Simone, Vogelzang, Erik Hans, Hooijberg, Femke, Hart, Margaretha Hendrika Louise, Bentlage, Arthur Ebel Herman, Thomas, Debby, Vermeire, Severine, Vidarsson, Gestur, ten Brinke, Anja, Nurmohamed, Michael Twahier, Wolbink, Gerrit Jan, and Rispens, Theo

Subjects
IMMUNE complexes, ULCERATIVE colitis, TUMOR necrosis factors, ADALIMUMAB, ETANERCEPT, THERAPEUTICS
Abstract

Background and Purpose: Millions of patients with inflammatory diseases are treated with tumour necrosis factor (TNF) inhibitors (TNFi). Individual treatment response varies, in part related to variable drug clearance. The role of TNF–TNFi complexes in clearance of the different TNFi is controversial. Moreover, mechanistic insight into the structural aspects and biological significance of TNF–TNFi complexes is lacking. We hypothesized a role for Fc‐mediated clearance of TNF–TNFi immune complexes. Therefore, we investigated circulating TNF–TNFi complexes upon treatment with certolizumab—lacking Fc tails—in comparison with adalimumab, golimumab, infliximab and etanercept. Experimental Approach: Drug‐tolerant ELISAs were developed and used to quantify TNF during adalimumab, golimumab, etanercept, certolizumab and infliximab treatment in patients with inflammatory arthritis or ulcerative colitis for a maximum follow‐up of 1 year. Effects on in vitro TNF production and Fc‐mediated uptake of TNF–TNFi complexes were investigated for all five TNFi. Key Results: Circulating TNF concentrations were >20‐fold higher during certolizumab treatment compared with adalimumab, reaching up to 23.1 ng·ml−1. Internalization of TNF–TNFi complexes by macrophages depended on Fc valency, with efficient uptake for the full antibody TNFi (three Fc tails), but little or no uptake for etanercept and certolizumab (one and zero Fc tail, respectively). TNF production was not affected by TNFi. Total TNF load did not affect clearance rate of total TNFi. Conclusions and Implications: Differences in TNFi structure profoundly affect clearance of TNF, while it is unlikely that TNF itself significantly contributes to target‐mediated drug disposition of TNFi. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Formation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment

Author

Berkhout, Lea Catharina, primary, I'Ami, Merel Jeanne, additional, Kruithof, Simone, additional, Vogelzang, Erik Hans, additional, Hooijberg, Femke, additional, Hart, Margaretha Hendrika Louise, additional, Bentlage, Arthur Ebel Herman, additional, Thomas, Debby, additional, Vermeire, Severine, additional, Vidarsson, Gestur, additional, ten Brinke, Anja, additional, Nurmohamed, Michael Twahier, additional, Wolbink, Gerrit Jan, additional, and Rispens, Theo, additional

Published
2023
Full Text
View/download PDF

13. Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod

Author

van Kempen, Zoé LE, primary, van Dam, Koos PJ, additional, Keijser, Jim BD, additional, Stalman, Eileen W, additional, Kummer, Laura YL, additional, Strijbis, Eva MM, additional, Steenhuis, Maurice, additional, ten Brinke, Anja, additional, van Ham, S. Marieke, additional, Kuijpers, Taco, additional, Rispens, Theo, additional, Eftimov, Filip, additional, Wieske, Luuk, additional, and Killestein, Joep, additional

Published
2023
Full Text
View/download PDF

14. Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.

Author

van Kempen, Zoé LE, van Dam, Koos PJ, Keijser, Jim BD, Stalman, Eileen W, Kummer, Laura YL, Strijbis, Eva MM, Steenhuis, Maurice, ten Brinke, Anja, van Ham, S. Marieke, Kuijpers, Taco, Rispens, Theo, Eftimov, Filip, Wieske, Luuk, and Killestein, Joep

Subjects
HUMORAL immunity, SARS-CoV-2 Omicron variant, SARS-CoV-2, VACCINATION, FINGOLIMOD
Abstract

Background: Humoral responses after SARS-CoV-2 vaccination are greatly impaired in multiple sclerosis (MS) patients on fingolimod. Effects of repeated vaccination and infections on long-term responses are unclear. Methods: Prospective study in 60 MS patients on fingolimod measuring humoral responses after up to four vaccinations and 8 months after fourth vaccination. Results: Anti-WH1 antibody titers increased with each additional vaccination. At long-term follow-up titers increased further and most patients developed new humoral responses against the BA.1 omicron variant. Conclusion: Repeated SARS-CoV-2 vaccinations boost humoral immunity and, probably together with SARS-CoV-2 infections, induce humoral responses on the long-term in almost all patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. <scp>DAMPS</scp> and complement activation in platelet concentrates that induce adverse reactions in patients

Author

de Wit, Yasmin E S, Hamzeh-Cognasse, Hind, Cognasse, Fabrice, Ten Brinke, Anja, Zeerleder, Sacha S, Graduate School, Landsteiner Laboratory, and ACS - Atherosclerosis & ischemic syndromes

Subjects
Blood Platelets, HMGB1, DAMPS, complement activation, febrile non-hemolytic reaction, Immunology, Transfusion Reaction, Platelet Transfusion, Hematology, Platelet Activation, P-Selectin, transfusion adverse reactions, platelet concentrates, Alarmins, Humans, Immunology and Allergy, HMGB1 Protein, 610 Medicine & health, transfusion
Abstract

BACKGROUND Patients with severe thrombocytopenia due to bone marrow failure and after chemotherapy are still treated with platelet transfusions. Platelet concentrates (PC) are associated with a high incidence of adverse reactions (AR). Platelet-derived damage-associated molecular patterns (DAMPS) and complement were proposed to play a role in the pathology of AR. STUDY DESIGN AND METHODS Single donor apheresis platelet concentrates (SDA PCs) were produced in a regional setting of the French Blood Establishment. After transfusion samples were collected from PC and possible AR in patients were recorded. Platelet activation markers, High mobility group box 1 (HMGB1) and complement activation products (CAP) were measured. The correlation between platelet activation, and HMGB1 and complement activation was analyzed. RESULTS A total of 56 PC were included in the study. 30 PC induced no AR, and 26 induced AR (Febrile non-hemolytic transfusion reaction n = 16; Atypical Allergic Transfusion Reactions n = 11; hemodynamic instability n = 5) in the patients. The levels of P-selectin, sCD40L, HMGB1, C3b/c, and C4b/c were all significantly increased in PC that induced AR following transfusion in patients. Additionally, HMGB1, C3b/c, and C4b/c were positively correlated with P-selectin and sCD40L. CONCLUSION In this study, we observed an association between HMGB1 and CAP and the incidence of AR. Furthermore, we demonstrated that both HMGB1 and complement activation were correlated to platelet activation.

Published
2022

19. Single-cell analysis reveals dynamics of human B cell differentiation and identifies novel B and antibody-secreting cell intermediates

Author

Verstegen, Niels JM, primary, Pollastro, Sabrina, primary, Unger, Peter-Paul A, additional, Marsman, Casper, additional, Elias, George, additional, Jorritsma, Tineke, additional, Streutker, Marij, additional, Bassler, Kevin, additional, Haendler, Kristian, additional, Rispens, Theo, additional, Schultze, Joachim L, additional, ten Brinke, Anja, additional, Beyer, Marc, additional, and van Ham, S Marieke, additional

Published
2023
Full Text
View/download PDF

20. Author response: Single-cell analysis reveals dynamics of human B cell differentiation and identifies novel B and antibody-secreting cell intermediates

Author

Verstegen, Niels JM, primary, Pollastro, Sabrina, primary, Unger, Peter-Paul A, additional, Marsman, Casper, additional, Elias, George, additional, Jorritsma, Tineke, additional, Streutker, Marij, additional, Bassler, Kevin, additional, Haendler, Kristian, additional, Rispens, Theo, additional, Schultze, Joachim L, additional, ten Brinke, Anja, additional, Beyer, Marc, additional, and van Ham, S Marieke, additional

Published
2023
Full Text
View/download PDF

21. Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

Author

Wieske, Luuk, primary, Stalman, Eileen W, additional, van Dam, P J Koos, additional, Kummer, Laura Y, additional, Steenhuis, Maurice, additional, van Kempen, Zoe L E, additional, Killestein, Joep, additional, Volkers, Adriaan G, additional, Tas, Sander W, additional, Boekel, Laura, additional, Wolbink, Gertjan, additional, Van der Kooi, Anneke, additional, Raaphorst, Joost, additional, Löwenberg, Mark, additional, Takkenberg, Bart, additional, D’Haens, Geert R A M, additional, Spuls, Phyllis I, additional, Bekkenk, Marcel W, additional, Musters, Annelie H, additional, Post, Nicoline F, additional, Bosma, Angela L, additional, Hilhorst, Marc L, additional, Vegting, Yosta, additional, Bemelman, Frederique J, additional, Voskuyl, Alexandre, additional, Broens, Bo, additional, Parra Sanchez, Agner, additional, van Els, Cécile A C M, additional, Wit, Jelle De, additional, Rutgers, Abraham, additional, de Leeuw, Karina, additional, Horváth, Barbara, additional, Verschuuren, Jan J G M, additional, Ruiter, Annabel M, additional, van Ouwerkerk, Lotte, additional, van der Woude, Diane, additional, Allaart, Cornelia F, additional, Teng, Y K Onno, additional, van Paassen, Pieter, additional, Busch, Matthias H, additional, Jallah, Papay B P, additional, Brusse, Esther, additional, van Doorn, Pieter A, additional, Baars, Adája Elisabeth, additional, Hijnen, Dirkjan, additional, Schreurs, Corine R G, additional, Van der Pol, W Ludo, additional, Goedee, H Stephan, additional, Keijzer, Sofie, additional, Keijser, Jim, additional, Cristianawati, Olvi, additional, ten Brinke, Anja, additional, Verstegen, Niels J M, additional, Zwinderman, Koos A H, additional, van Ham, S Marieke, additional, Kuijpers, Taco W, additional, Rispens, Theo, additional, and Eftimov, Filip, additional

Published
2023
Full Text
View/download PDF

22. Longitudinal Dynamics of the SARS-CoV-2 Antibody Repertoire after SARS-CoV-2 Delta and Omicron Breakthrough Infections in Patients with Immune-Mediated Inflammatory Diseases

Author

Stalman, Eileen, primary, Wieske, Luuk, additional, Keijser, Jim, additional, van Dam, Koos, additional, Kummer, Laura, additional, Wilbrink, Maarten F., additional, van Kempen, Zoé, additional, Killestein, Joep, additional, Volkers, Adriaan G., additional, Tas, Sander, additional, Boekel, Laura, additional, Wolbink, Gertjan, additional, van der Kooi, Anneke J., additional, Raaphorst, Joost, additional, Löwenberg, Mark, additional, Takkenberg, R. Bart, additional, D&apos;Haens, Geert R.A.M., additional, Spuls, Phyllis I., additional, Bekkenk, Marcel W., additional, Musters, Annelie H., additional, Post, Nicoline F., additional, Bosma, Angela L., additional, Hilhorst, Marc L., additional, Vegting, Yosta, additional, Bemelman, Frederike J., additional, Voskuyl, Alexandre, additional, Broens, Bo, additional, Sanchez, Agner Parra, additional, van Els, Cecile, additional, de Wit, Jelle, additional, Rutgers, Abraham, additional, de Leeuw, Karina, additional, Horváth, Barbara, additional, Verschuuren, Jan J.G.M., additional, Ruiter, Annabel M., additional, van Ouwerkerk, Lotte, additional, van der Woude, Diane, additional, Allaart, Cornelia F., additional, Teng, Onno YK, additional, van Paassen, Pieter, additional, Busch, Matthias, additional, Brusse, Esther, additional, van Doorn, Pieter, additional, Baars, Adája E., additional, Hijnen, Dirk Jan, additional, Schreurs, Corine R.G., additional, van der Pol, Ludo, additional, Goedee, H. Stephan, additional, Steenhuis, Maurice, additional, Keijzer, Sofie, additional, Cristianawati, Olvi, additional, ten Brinke, Anja, additional, Verstegen, Niels, additional, Zwinderman, Aeilko H., additional, van Ham, Marieke, additional, Rispens, Theo, additional, Welkers, Matthijs R.A., additional, Jonges, Marcel, additional, Eftimov, Filip, additional, and Kuijpers, Taco, additional

Published
2023
Full Text
View/download PDF

25. Additional file 1 of Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

Author

van Dam, Koos P. J., Volkers, Adriaan G., Wieske, Luuk, Stalman, Eileen W., Kummer, Laura Y. L., van Kempen, Zoé L. E., Killestein, Joep, Tas, Sander W., Boekel, Laura, Wolbink, Gerrit J., van der Kooi, Anneke J., Raaphorst, Joost, Takkenberg, R. Bart, D’Haens, Geert R. A. M., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Hilhorst, Marc L., Vegting, Yosta, Bemelman, Frederike J., Voskuyl, Alexandre E., Broens, Bo, Sanchez, Agner Parra, van Els, Cécile A. C. M., de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J. G. M., Ruiter, Annabel M., van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Renée C. F., Teng, Y. K. Onno, van Paassen, Pieter, Busch, Matthias H., Jallah, Papay B. P., Brusse, Esther, van Doorn, Pieter A., Baars, Adája E., Hijnen, Dirk Jan, Schreurs, Corine R. G., van der Pol, W. Ludo, Goedee, H. Stephan, Steenhuis, Maurice, Keijzer, Sofie, Keijser, Jim B. D., Cristianawati, Olvi, ten Brinke, Anja, Verstegen, Niels J. M., van Ham, S. Marieke, Rispens, Theo, Kuijpers, Taco W., Löwenberg, Mark, and Eftimov, Filip

Abstract

Additional file 1.

Published
2023
Full Text
View/download PDF

26. SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis

Author

van Kempen, Zoé L E, primary, Stalman, Eileen W, additional, Steenhuis, Maurice, additional, Kummer, Laura Y L, additional, van Dam, Koos P J, additional, Wilbrink, Maarten F, additional, ten Brinke, Anja, additional, van Ham, S Marieke, additional, Kuijpers, Taco, additional, Rispens, Theo, additional, Eftimov, Filip, additional, Wieske, Luuk, additional, and Killestein, Joep, additional

Published
2022
Full Text
View/download PDF

28. Single-cell analysis reveals dynamics of human B cell differentiation and identifies novel B and antibody-secreting cell intermediates

Author

Verstegen, Niels J.M., primary, Pollastro, Sabrina, additional, Unger, Peter-Paul A., additional, Marsman, Casper, additional, Elias, George, additional, Jorritsma, Tineke, additional, Streutker, Marij, additional, Baβler, Kevin, additional, Händler, Kristian, additional, Rispens, Theo, additional, Schultze, Joachim L., additional, ten Brinke, Anja, additional, Beyer, Marc, additional, and van Ham, S. Marieke, additional

Published
2022
Full Text
View/download PDF

29. Phagocytosis of platelets opsonized with differently glycosylated anti-HLA hIgG1 by monocyte-derived macrophages

Author

van Osch, Thijs L. J., primary, Steuten, Juulke, additional, Nouta, Jan, additional, Koeleman, Carolien A. M., additional, Bentlage, Arthur E. H., additional, Heidt, Sebastiaan, additional, Mulder, Arend, additional, Voorberg, Jan, additional, van Ham, S. Marieke, additional, Wuhrer, Manfred, additional, ten Brinke, Anja, additional, and Vidarsson, Gestur, additional

Published
2022
Full Text
View/download PDF

30. Measurement of post-transfusion red blood cell survival kinetics in sickle cell disease and β-Thalassemia: A biotin label approach

Author

Gerritsma, Jorn J., van der Bolt, Nieke, van Bruggen, Robin, ten Brinke, Anja, van Dam, John, Guerrero, Guillermo, Vermeulen, Christie, de Bruin, Sanne, Vlaar, Alexander P. J., Biemond, Bart J., Nur, Erfan, van der Schoot, Ellen, Fijnvandraat, Karin, Graduate School, ACS - Pulmonary hypertension & thrombosis, Landsteiner Laboratory, Intensive Care Medicine, ACS - Microcirculation, AII - Inflammatory diseases, Clinical Haematology, Paediatric Haematology, and ARD - Amsterdam Reproduction and Development

Subjects
Adult, Erythrocytes, beta-Thalassemia/therapy, Biotin, Humans, Prospective Studies, Anemia, Sickle Cell/therapy
Abstract

Background: Red blood cell (RBC) transfusions are an important treatment modality for patients with sickle cell disease (SCD) and β-thalassemia. A subgroup of these patients relies on a chronic RBC transfusion regimen. Little is known about RBC survival (RCS) of the transfused allogeneic RBCs. In this study, we aimed to study the RCS kinetics of transfused RBCs in SCD and β-thalassemia and to investigate factors that determine RCS. Methods and Materials: We performed a prospective cohort study on fourteen adults with SCD and β-thalassemia disease receiving a chronic transfusion regimen. RCS and the influence of donor and patient characteristics on RCS were assessed by simultaneous transfusion of two allogeneic RBCs using RBC biotinylation. Phenotyping of well-known RBC markers over time was performed using flow cytometry. Results: RCS of the two transfused RBC units was similar in most patients. Although intra-individual variation was small, inter-individual variation in RCS kinetics was observed. Most patients demonstrated a non-linear trend in RCS that was different from the observed linear RCS kinetics in healthy volunteers. After an initial slight increase in the proportion of biotinylated RBCs during the first 24 h, a rapid decrease within the first 10–12 days was followed by a slower clearance rate. Conclusion: These are the first data to demonstrate that patient-related factors largely determine post-transfusion RCS behavior of donor RBC in SCD and β-thalassemia, while donor factors exert a negligible effect. Further assessment and modeling of RCS kinetics and its determinants in SCD and β-thalassemia patients may ultimately improve transfusion therapy.

Published
2022

32. Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases

Author

Stalman, Eileen W, primary, Wieske, Luuk, additional, van Dam, Koos P J, additional, Kummer, Laura Y, additional, van Kempen, Zoé L E, additional, Killestein, Joep, additional, Volkers, Adriaan G, additional, Tas, Sander W, additional, Boekel, Laura, additional, Wolbink, Gertjan J, additional, Van der Kooi, Anneke J, additional, Raaphorst, Joost, additional, Löwenberg, Mark, additional, Takkenberg, R Bart, additional, D’Haens, Geert R A M, additional, Spuls, Phyllis I, additional, Bekkenk, Marcel W, additional, Musters, Annelie H, additional, Post, Nicoline F, additional, Bosma, Angela L, additional, Hilhorst, Marc L, additional, Vegting, Yosta, additional, Bemelman, Frederique J, additional, Voskuyl, Alexandre E, additional, Broens, Bo, additional, Parra Sanchez, Agner, additional, van Els, Cécile A C M, additional, Wit, Jelle De, additional, Rutgers, Abraham, additional, de Leeuw, Karina, additional, Horváth, Barbara, additional, Verschuuren, Jan J G M, additional, Ruiter, Annabel M, additional, van Ouwerkerk, Lotte, additional, van der Woude, Diane, additional, Allaart, C F, additional, Teng, Onno Y K, additional, van Paassen, Pieter, additional, Busch, Matthias H, additional, Jallah, Papay B P, additional, Brusse, Esther, additional, van Doorn, Pieter A, additional, Baars, Adája Elisabeth, additional, Hijnen, Dirk Jan, additional, Schreurs, Corine R G, additional, Van der Pol, W Ludo, additional, Goedee, H Stephan, additional, Steenhuis, Maurice, additional, Keijzer, Sofie, additional, Keijser, Jim B D, additional, Boogaard, Arend, additional, Cristianawati, Olvi, additional, ten Brinke, Anja, additional, Verstegen, Niels J M, additional, Zwinderman, Koos A H, additional, Rispens, Theo, additional, van Ham, S Marieke, additional, Kuijpers, Taco W, additional, and Eftimov, Filip, additional

Published
2022
Full Text
View/download PDF

36. SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis.

Author

van Kempen, Zoé L. E., Stalman, Eileen W., Steenhuis, Maurice, Kummer, Laura Y. L., van Dam, Koos P. J., Wilbrink, Maarten F., ten Brinke, Anja, Marieke van Ham, S., Kuijpers, Taco, Rispens, Theo, Eftimov, Filip, Wieske, Luuk, and Killestein, Joep

Subjects
BREAKTHROUGH infections, SARS-CoV-2 Omicron variant, MULTIPLE sclerosis, SARS-CoV-2, CONVALESCENT plasma, JOHN Cunningham virus
Published
2023
Full Text
View/download PDF

39. Author response: Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273

Author

Verstegen, Niels JM, primary, Hagen, Ruth R, additional, van den Dijssel, Jet, additional, Kuijper, Lisan H, additional, Kreher, Christine, additional, Ashhurst, Thomas, additional, Kummer, Laura YL, additional, Steenhuis, Maurice, additional, Duurland, Mariel, additional, de Jongh, Rivka, additional, de Jong, Nina, additional, van der Schoot, C Ellen, additional, Bos, Amélie V, additional, Mul, Erik, additional, Kedzierska, Katherine, additional, van Dam, Koos PJ, additional, Stalman, Eileen W, additional, Boekel, Laura, additional, Wolbink, Gertjan, additional, Tas, Sander W, additional, Killestein, Joep, additional, van Kempen, Zoé LE, additional, Wieske, Luuk, additional, Kuijpers, Taco W, additional, Eftimov, Filip, additional, Rispens, Theo, additional, van Ham, S Marieke, additional, ten Brinke, Anja, additional, and van de Sandt, Carolien E, additional

Published
2022
Full Text
View/download PDF

40. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

Author

Boekel, Laura, primary, Stalman, Eileen W, additional, Wieske, Luuk, additional, Hooijberg, Femke, additional, van Dam, Koos P J, additional, Besten, Yaëlle R, additional, Kummer, Laura Y L, additional, Steenhuis, Maurice, additional, van Kempen, Zoé L E, additional, Killestein, Joep, additional, Volkers, Adriaan G, additional, Tas, Sander W, additional, van der Kooi, Anneke J, additional, Raaphorst, Joost, additional, Löwenberg, Mark, additional, Takkenberg, R Bart, additional, D'Haens, Geert R A M, additional, Spuls, Phyllis I, additional, Bekkenk, Marcel W, additional, Musters, Annelie H, additional, Post, Nicoline F, additional, Bosma, Angela L, additional, Hilhorst, Marc L, additional, Vegting, Yosta, additional, Bemelman, Frederike J, additional, Voskuyl, Alexandre E, additional, Broens, Bo, additional, Parra Sanchez, Agner, additional, van Els, Cécile A C M, additional, de Wit, Jelle, additional, Rutgers, Abraham, additional, de Leeuw, Karina, additional, Horváth, Barbara, additional, Verschuuren, Jan J G M, additional, Ruiter, Annabel M, additional, van Ouwerkerk, Lotte, additional, van der Woude, Diane, additional, Allaart, Cornelia F, additional, Teng, Y K Onno, additional, van Paassen, Pieter, additional, Busch, Matthias H, additional, Jallah, Papay B P, additional, Brusse, Esther, additional, van Doorn, Pieter A, additional, Baars, Adája E, additional, Hijnen, Dirk Jan, additional, Schreurs, Corine R G, additional, van der Pol, W Ludo, additional, Goedee, H Stephan, additional, Vogelzang, Erik H, additional, Leeuw, Maureen, additional, Atiqi, Sadaf, additional, van Vollenhoven, Ronald, additional, Gerritsen, Martijn, additional, van der Horst-Bruinsma, Irene E, additional, Lems, Willem F, additional, Nurmohamed, Mike T, additional, Boers, Maarten, additional, Keijzer, Sofie, additional, Keijser, Jim, additional, van de Sandt, Carolien, additional, Boogaard, Arend, additional, Cristianawati, Olvi, additional, ten Brinke, Anja, additional, Verstegen, Niels J M, additional, Zwinderman, Koos A H, additional, van Ham, S Marieke, additional, Rispens, Theo, additional, Kuijpers, Taco W, additional, Wolbink, Gertjan, additional, Eftimov, Filip, additional, de Jongh, Rivka, additional, Kuijper, Lisan, additional, Duurland, Mariel, additional, Hagen, Ruth, additional, van den Dijssel, Jet, additional, Kreher, Christine, additional, Bos, Amelie, additional, Palomares Cabeza, Viriginia, additional, Konijn, Veronique, additional, Elias, George, additional, Vallejo, Juan, additional, van Gils, Marrit, additional, Ashhurst, Tom, additional, Nejentsev, Sergey, additional, and Mirfazeli, Elham, additional

Published
2022
Full Text
View/download PDF

41. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

Author

Wieske, Luuk, primary, van Dam, Koos P J, additional, Steenhuis, Maurice, additional, Stalman, Eileen W, additional, Kummer, Laura Y L, additional, van Kempen, Zoé L E, additional, Killestein, Joep, additional, Volkers, Adriaan G, additional, Tas, Sander W, additional, Boekel, Laura, additional, Wolbink, Gerrit J, additional, van der Kooi, Anneke J, additional, Raaphorst, Joost, additional, Löwenberg, Mark, additional, Takkenberg, R Bart, additional, D'Haens, Geert R A M, additional, Spuls, Phyllis I, additional, Bekkenk, Marcel W, additional, Musters, Annelie H, additional, Post, Nicoline F, additional, Bosma, Angela L, additional, Hilhorst, Marc L, additional, Vegting, Yosta, additional, Bemelman, Frederike J, additional, Voskuyl, Alexandre E, additional, Broens, Bo, additional, Sanchez, Agner Parra, additional, van Els, Cécile A C M, additional, de Wit, Jelle, additional, Rutgers, Abraham, additional, de Leeuw, Karina, additional, Horváth, Barbara, additional, Verschuuren, Jan J G M, additional, Ruiter, Annabel M, additional, van Ouwerkerk, Lotte, additional, van der Woude, Diane, additional, Allaart, Renée C F, additional, Teng, Y K Onno, additional, van Paassen, Pieter, additional, Busch, Matthias H, additional, Jallah, Papay B P, additional, Brusse, Esther, additional, van Doorn, Pieter A, additional, Baars, Adája E, additional, Hijnen, Dirk Jan, additional, Schreurs, Corine R G, additional, van der Pol, W Ludo, additional, Goedee, H Stephan, additional, Keijzer, Sofie, additional, Keijser, Jim B D, additional, Boogaard, Arend, additional, Cristianawati, Olvi, additional, ten Brinke, Anja, additional, Verstegen, Niels J M, additional, Zwinderman, Koos A H, additional, van Ham, S Marieke, additional, Kuijpers, Taco W, additional, Rispens, Theo, additional, Eftimov, Filip, additional, de Jongh, R., additional, van de Sandt, C.E., additional, Kuijper, L., additional, Duurland, M., additional, Hagen, R.R., additional, van den Dijssel, J., additional, Kreher, C., additional, Bos, A., additional, Palomares Cabeza, V., additional, Konijn, V.A.L., additional, Elias, G., additional, Vallejo, J.G., additional, van Gils, M.J., additional, Ashhurst, T.M., additional, Nejentsev, S., additional, and Mirfazeli, E.S., additional

Published
2022
Full Text
View/download PDF

44. Additional file 2 of Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases

Author

Wieske, Luuk, Kummer, Laura Y. L., van Dam, Koos P. J., Stalman, Eileen W., van der Kooi, Anneke J., Raaphorst, Joost, L��wenberg, Mark, Takkenberg, R. Bart, Volkers, Adriaan G., D���Haens, Geert R. A. M., Tas, Sander W., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Hilhorst, Marc L., Vegting, Yosta, Bemelman, Frederike J., Killestein, Joep, van Kempen, Zo�� L. E., Voskuyl, Alexandre E., Broens, Bo, Sanchez, Agner Parra, Wolbink, Gertjan, Boekel, Laura, Rutgers, Abraham, de Leeuw, Karina, Horv��th, Barbara, Verschuuren, Jan J. G. M., Ruiter, Annabel M., van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Cornelia F., Teng, Y. K. Onno, van Paassen, Pieter, Busch, Matthias H., Jallah, B. Papay, Brusse, Esther, van Doorn, Pieter A., Baars, Ad��ja E., Hijnen, Dirkjan, Schreurs, Corine R. G., van der Pol, W. Ludo, Goedee, H. Stephan, Steenhuis, Maurice, Rispens, Theo, ten Brinke, Anja, Verstegen, Niels J. M., Zwinderman, Koos A. H., van Ham, S. Marieke, Kuijpers, Taco W., and Eftimov, Filip

Subjects
body regions, viruses, fungi, skin and connective tissue diseases, respiratory tract diseases
Abstract

Additional file 2: Table S1. Demographics. Figure S1. Study flowchart. Figure S2. Adverse events in patients with IMIDs after SARS-CoV-2 vaccination. Figure S3. Adverse events after SARS-CoV-2 vaccination per IMID.

Published
2022
Full Text
View/download PDF

45. Parallel detection of SARS-CoV-2 epitopes reveals dynamic immunodominance profiles of CD8+ T memory cells in convalescent COVID-19 donors

Author

van den Dijssel, Jet, Hagen, Ruth R., de Jongh, Rivka, Steenhuis, Maurice, Rispens, Theo, Geerdes, Dionne M., Mok, Juk Yee, Kragten, Angela H. M., Duurland, Mariël C., Verstegen, Niels J. M., van Ham, S. Marieke, van Esch, Wim J. E., van Gisbergen, Klaas P. JM, Hombrink, Pleun, ten Brinke, Anja, van de Sandt, Carolien E., Graduate School, Landsteiner Laboratory, AII - Inflammatory diseases, Experimental Immunology, and AII - Infectious diseases

Subjects
immunodominance, SARS-CoV-2, CD8 T cells, convalescence, epitopes, infection
Abstract

Objectives: High-magnitude CD8+ T cell responses are associated with mild COVID-19 disease; however, the underlying characteristics that define CD8+ T cell-mediated protection are not well understood. The antigenic breadth and the immunodominance hierarchies of epitope-specific CD8+ T cells remain largely unexplored and are essential for the development of next-generation broad-protective vaccines. This study identified a broad spectrum of conserved SARS-CoV-2 CD8+ T cell epitopes and defined their respective immunodominance and phenotypic profiles following SARS-CoV-2 infection. Methods: CD8+ T cells from 51 convalescent COVID-19 donors were analysed for their ability to recognise 133 predicted and previously described SARS-CoV-2-derived peptides restricted by 11 common HLA class I allotypes using heterotetramer combinatorial coding, which combined with phenotypic markers allowed in-depth ex vivo profiling of CD8+ T cell responses at quantitative and phenotypic levels. Results: A comprehensive panel of 49 mostly conserved SARS-CoV-2-specific CD8+ T cell epitopes, including five newly identified low-magnitude epitopes, was established. We confirmed the immunodominance of HLA-A*01:01/ORF1ab1637–1646 and B*07:02/N105–113 and identified B*35:01/N325–333 as a third epitope with immunodominant features. The magnitude of subdominant epitope responses, including A*03:01/N361–369 and A*02:01/S269–277, depended on the donors' HLA-I context. All epitopes expressed prevalent memory phenotypes, with the highest memory frequencies in severe COVID-19 donors. Conclusion: SARS-CoV-2 infection induces a predominant CD8+ T memory response directed against a broad spectrum of conserved SARS-CoV-2 epitopes, which likely contributes to long-term protection against severe disease. The observed immunodominance hierarchy emphasises the importance of T cell epitopes derived from nonspike proteins to the overall protective and cross-reactive immune response, which could aid future vaccine strategies.

Published
2022

46. Additional file 1 of Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases

Author

Wieske, Luuk, Kummer, Laura Y. L., van Dam, Koos P. J., Stalman, Eileen W., van der Kooi, Anneke J., Raaphorst, Joost, L��wenberg, Mark, Takkenberg, R. Bart, Volkers, Adriaan G., D���Haens, Geert R. A. M., Tas, Sander W., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Hilhorst, Marc L., Vegting, Yosta, Bemelman, Frederike J., Killestein, Joep, van Kempen, Zo�� L. E., Voskuyl, Alexandre E., Broens, Bo, Sanchez, Agner Parra, Wolbink, Gertjan, Boekel, Laura, Rutgers, Abraham, de Leeuw, Karina, Horv��th, Barbara, Verschuuren, Jan J. G. M., Ruiter, Annabel M., van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Cornelia F., Teng, Y. K. Onno, van Paassen, Pieter, Busch, Matthias H., Jallah, B. Papay, Brusse, Esther, van Doorn, Pieter A., Baars, Ad��ja E., Hijnen, Dirkjan, Schreurs, Corine R. G., van der Pol, W. Ludo, Goedee, H. Stephan, Steenhuis, Maurice, Rispens, Theo, ten Brinke, Anja, Verstegen, Niels J. M., Zwinderman, Koos A. H., van Ham, S. Marieke, Kuijpers, Taco W., and Eftimov, Filip

Abstract

Additional file 1. Adverse events questionnaire.

Published
2022
Full Text
View/download PDF

47. Platelet concentrates in platelet additive solutions generate less complement activation products during storage than platelets stored in plasma

Author

de Wit, Yasmin E. S., Vlaar, Richard, Gouwerok, Eric, Hamzeh-Cognasse, Hind, van Mierlo, Gerard, Bulder, Ingrid, Lagerberg, Johan W. M., de Korte, Dirk, Cognasse, Fabrice, ten Brinke, Anja, Zeerleder, Sacha S., Graduate School, AII - Inflammatory diseases, and AII - Infectious diseases

Subjects
610 Medicine & health
Abstract

BACKGROUND Platelet transfusions can be associated with adverse reactions, such as febrile non-haemolytic transfusion reaction (FNHTR). It has been suggested that damage-associated molecular patterns (DAMP) and complement play a role in FNHTR. This study investigated the nature of DAMPs and complement activation products contained in platelet concentrates during storage, with a specific focus on different platelet storage solutions. MATERIALS AND METHODS Buffy coats (BC) from healthy donors were pooled (15 BC per pool) and divided into three groups of the same volume. After addition of different storage solutions (plasma, platelet additive solutions [PAS]-C or PAS-E; n=6 for each group), BC pools were processed to platelet concentrates (PC). Leukoreduced PCs were stored on a shaking bed at 20-24��C and sampled on days 1, 2, 6 and 8 after collection for selected quality parameters: platelet activation, DAMPs (High Mobility Group Box 1 [HMGB1], nucleosomes), and complement activation products. RESULTS During storage, equal levels of free nucleosomes and increasing concentrations of HMGB1 were present in all groups. Complement activation was observed in all PC. However, by day 8, the use of PAS had reduced C3b/c levels by approximately 90% and C4b/c levels by approximately 65%. DISCUSSION Nucleosomes and HMGB1 were present in PCs prepared in plasma and PAS. Complement was activated during storage of platelets in plasma and in PAS. The use of PAS is associated with a lower amount of complement activation products due to the dilution of plasma by PAS. Therefore, PC in PAS have less complement activation products than platelets stored in plasma. These proinflammatory mediators in PC might induce FNHTR.

Published
2022
Full Text
View/download PDF

49. Phagocytosis of platelets opsonized with differently glycosylated anti-HLA hIgG1 by monocyte-derived macrophages.

Author

van Osch, Thijs L. J., Steuten, Juulke, Nouta, Jan, Koeleman, Carolien A. M., Bentlage, Arthur E. H., Heidt, Sebastiaan, Mulder, Arend, Voorberg, Jan, van Ham, S. Marieke, Wuhrer, Manfred, ten Brinke, Anja, and Vidarsson, Gestur

Subjects
HISTOCOMPATIBILITY class I antigens, PHAGOCYTOSIS, BLOOD platelets, MACROPHAGES, BLOOD platelet transfusion
Abstract

Immune-mediated platelet refractoriness (PR) remains a significant problem in the setting of platelet transfusion and is predominantly caused by the presence of alloantibodies directed against class I human leukocyte antigens (HLA). Opsonization of donor platelets with these alloantibodies can result in rapid clearance after transfusion via multiple mechanisms, including antibody dependent cellular phagocytosis (ADCP). Interestingly, not all alloimmunized patients develop PR to unmatched platelet transfusions, suggesting variation in HLA-specific IgG responses between patients. Previously, we observed that the glycosylation profile of anti-HLA antibodies was highly variable between PR patients, especially with respect to Fc galactosylation, sialylation and fucosylation. In the current study, we investigated the effect of different Fc glycosylation patterns, with known effects on complement deposition and FcγR binding, on phagocytosis of opsonized platelets by monocyte-derived human macrophages. We found that the phagocytosis of antibody- and complement-opsonized platelets, by monocyte derived M1 macrophages, was unaffected by these qualitative IgG-glycan differences. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis.

Author

van Kempen, Zoé L. E., Hogenboom, Laura, Toorop, Alyssa A., Steenhuis, Maurice, Stalman, Eileen W., Kummer, Laura Y. L., van Dam, Koos P. J., Bloem, Karien, ten Brinke, Anja, van Ham, S. Marieke, Kuijpers, Taco W., Wolbink, Gerrit J., Loeff, Floris C., Wieske, Luuk, Eftimov, Filip, Rispens, Theo, Strijbis, Eva M. M., and Killestein, Joep

Subjects
MULTIPLE sclerosis, SARS-CoV-2, VACCINATION, HUMORAL immunity, MONOCLONAL antibodies
Abstract

Ocrelizumab, an anti‐CD20 monoclonal antibody, counteracts induction of humoral immune responses after severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) vaccinations in patients with multiple sclerosis (MS). We aimed to assess if serum ocrelizumab concentration measured at the time of vaccination could predict the humoral response after SARS‐CoV‐2 vaccination. In 52 patients with MS, we found ocrelizumab concentration at the time of vaccination to be a good predictor for SARS‐CoV‐2 IgG anti‐RBD titers after vaccination (comparable to B‐cell count). As the course of ocrelizumab concentration may be predicted using pharmacokinetic models, this may be a superior biomarker to guide optimal timing for vaccinations in B‐cell depleted patients with MS. ANN NEUROL 2023;93:103–108 [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results